PLK1 and hepatocellular carcinoma: Recent studies have demonstrated that HCC cells harboring TERTp mutations are more sensitive to PLK1 inhibitors, suggesting that combining telomerase inhibition with PLK1-targeted therapy could enhance treatment efficacy in these tumors [48].